Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2013

Open Access 01-12-2013 | Research article

TP53 genetic polymorphisms, interactions with lifestyle factors and lung cancer risk: a case control study in a Chinese population

Authors: Yanli Li, Shen-Chih Chang, Rungui Niu, Li Liu, Christina R Crabtree-Ide, Baoxing Zhao, Jianping Shi, Xiaoyou Han, Jiawei Li, Jia Su, Lin Cai, Shunzhang Yu, Zuo-Feng Zhang, Lina Mu

Published in: BMC Cancer | Issue 1/2013

Login to get access

Abstract

Background

A pathway-based genotyping analysis suggested rs2078486 was a novel TP53 SNP, but very few studies replicate this association. TP53 rs1042522 is the most commonly studied SNP, but very few studies examined its potential interaction with environmental factors in relation to lung cancer risk. This study aims to examine associations between two TP53 single-nucleotide polymorphisms (SNPs) (rs2078486, rs1042522), their potential interaction with environmental factors and risk of lung cancer.

Methods

A case–control study was conducted in Taiyuan, China. Unconditional logistic regression was used to estimate odds ratios (ORs) and 95% confidence intervals (95% CIs). Multiplicative and additive interactions between TP53 SNPs and lifestyle factors were evaluated.

Results

Variant TP53 rs2078486 SNP was significantly associated with elevated lung cancer risk among smokers (OR: 1.70, 95% CI: 1.08 - 2.67) and individuals with high indoor air pollution exposure (OR: 1.51, 95% CI: 1.00-2.30). Significant or borderline significant multiplicative and additive interactions were found between TP53 rs2078486 polymorphism with smoking and indoor air pollution exposure. The variant genotype of TP53 SNP rs1042522 significantly increased lung cancer risk in the total population (OR: 1.57, 95% CI: 1.11-2.21), but there was no evidence of heterogeneity among individuals with different lifestyle factors.

Conclusions

This study confirmed that TP53 rs2078486 SNP is potentially a novel TP53 SNP that may affect lung cancer risk. Our study also suggested potential synergetic effects of TP53 rs2078486 SNP with smoking and indoor air pollution exposure on lung cancer risk.
Appendix
Available only for authorised users
Literature
1.
Parkin DM, Bray F, Ferlay J, Pisani P: Global cancer statistics, 2002. CA Cancer J Clin. 2005, 55 (2): 74-108. 10.3322/canjclin.55.2.74.CrossRefPubMed
2.
Zhao P, Dai M, Chen W, Li N: Cancer trends in China. Jpn J Clin Oncol. 2010, 40 (4): 281-285. 10.1093/jjco/hyp187.CrossRefPubMed
3.
Lam WK, White NW, Chan-Yeung MM: Lung cancer epidemiology and risk factors in Asia and Africa. Int J Tuberc Lung Dis. 2004, 8 (9): 1045-1057.PubMed
4.
Kiyohara C, Otsu A, Shirakawa T, Fukuda S, Hopkin JM: Genetic polymorphisms and lung cancer susceptibility: a review. Lung Cancer. 2002, 37 (3): 241-256. 10.1016/S0169-5002(02)00107-1.CrossRefPubMed
5.
Whibley C, Pharoah PD, Hollstein M: p53 polymorphisms: cancer implications. Nat Rev Cancer. 2009, 9 (2): 95-107. 10.1038/nrc2584.CrossRefPubMed
6.
Grochola LF, Zeron-Medina J, Meriaux S, Bond GL: Single-nucleotide polymorphisms in the p53 signaling pathway. Cold Spring Harb Perspect Biol. 2010, 2 (5): a001032-CrossRefPubMedPubMedCentral
7.
Francisco G, Menezes PR, Eluf-Neto J, Chammas R: Arg72Pro TP53 polymorphism and cancer susceptibility: a comprehensive meta-analysis of 302 case–control studies. Int J Cancer. 2011, 129 (4): 920-930. 10.1002/ijc.25710.CrossRefPubMed
8.
Yan L, Zhang D, Chen C, Mao Y, Xie Y, Li Y, Huang Y, Han B: TP53 Arg72Pro polymorphism and lung cancer risk: a meta-analysis. Int J Cancer. 2009, 125 (12): 2903-2911. 10.1002/ijc.24603.CrossRefPubMed
9.
Bellini MF, Cadamuro AC, Succi M, Proenca MA, Silva AE: Alterations of the TP53 gene in gastric and esophageal carcinogenesis. J Biomed Biotechnol. 2012, 2012: 891961-CrossRefPubMedPubMedCentral
10.
Spitz MR, Gorlov IP, Amos CI, Dong Q, Chen W, Etzel CJ, Gorlova OY, Chang DW, Pu X, Zhang D, et al: Variants in inflammation genes are implicated in risk of lung cancer in never smokers exposed to second-hand smoke. Cancer Discov. 2011, 1 (5): 420-429. 10.1158/2159-8290.CD-11-0080.CrossRefPubMedPubMedCentral
11.
Wang YR, Zhang Z, Wang YR, Zhang Z-F: Genetic variations in double-strand break DNA repair pathway and lung cancer upper & aerodigestive tract cancer. 3446869. 2010, Los Angeles: University of California
12.
Kazma R, Babron MC, Gaborieau V, Genin E, Brennan P, Hung RJ, McLaughlin JR, Krokan HE, Elvestad MB, Skorpen F, et al: Lung cancer and DNA repair genes: multilevel association analysis from the International Lung Cancer Consortium. Carcinogenesis. 2012, 33 (5): 1059-1064. 10.1093/carcin/bgs116.CrossRefPubMedPubMedCentral
13.
Schildkraut JM, Iversen ES, Wilson MA, Clyde MA, Moorman PG, Palmieri RT, Whitaker R, Bentley RC, Marks JR, Berchuck A: Association between DNA damage response and repair genes and risk of invasive serous ovarian cancer. PLoS One. 2010, 5 (4): e10061-10.1371/journal.pone.0010061.CrossRefPubMedPubMedCentral
14.
Yang Y, Xiao Z, Chen W, Sang H, Guan Y, Peng Y, Zhang D, Gu Z, Qian M, He G, et al: Tumor suppressor gene TP53 is genetically associated with schizophrenia in the Chinese population. Neurosci Lett. 2004, 369 (2): 126-131. 10.1016/j.neulet.2004.07.068.CrossRefPubMed
15.
Matlashewski GJ, Tuck S, Pim D, Lamb P, Schneider J, Crawford LV: Primary structure polymorphism at amino acid residue 72 of human p53. Mol Cell Biol. 1987, 7 (2): 961-963.CrossRefPubMedPubMedCentral
16.
Mu L, Liu L, Niu R, Zhao B, Shi J, Li Y, Swanson M, Scheider W, Su J, Chang SC, et al: Indoor air pollution and risk of lung cancer among Chinese female non-smokers. Cancer Causes Control. 2013, 24 (3): 439-450. 10.1007/s10552-012-0130-8.CrossRefPubMedPubMedCentral
17.
Ortiz-Cuaran S, Cox D, Villar S, Friesen MD, Durand G, Chabrier A, Khuhaprema T, Sangrajrang S, Ognjanovic S, Groopman JD, et al: Association between TP53 R249S mutation and polymorphisms in TP53 intron 1 in hepatocellular carcinoma. Genes Chromosomes Cancer. 2013, 52 (10): 912-919. 10.1002/gcc.22086.CrossRefPubMed
18.
Pangilinan F, Molloy AM, Mills JL, Troendle JF, Parle-McDermott A, Signore C, O’Leary VB, Chines P, Seay JM, Geiler-Samerotte K, et al: Evaluation of common genetic variants in 82 candidate genes as risk factors for neural tube defects. BMC Med Genet. 2012, 13: 62-10.1186/1471-2350-13-62.CrossRefPubMedPubMedCentral
19.
Andersson T, Alfredsson L, Kallberg H, Zdravkovic S, Ahlbom A: Calculating measures of biological interaction. Eur J Epidemiol. 2005, 20 (7): 575-579. 10.1007/s10654-005-7835-x.CrossRefPubMed
20.
Robles AI, Linke SP, Harris CC: The p53 network in lung carcinogenesis. Oncogene. 2002, 21 (45): 6898-6907. 10.1038/sj.onc.1205563.CrossRefPubMed
21.
Levine AJ: p53, the cellular gatekeeper for growth and division. Cell. 1997, 88 (3): 323-331. 10.1016/S0092-8674(00)81871-1.CrossRefPubMed
22.
Riley T, Sontag E, Chen P, Levine A: Transcriptional control of human p53-regulated genes. Nat Rev Mol Cell Biol. 2008, 9 (5): 402-412. 10.1038/nrm2395.CrossRefPubMed
23.
Moll UM, Schramm LM: p53–an acrobat in tumorigenesis. Crit Rev Oral Biol Med. 1998, 9 (1): 23-37. 10.1177/10454411980090010101.CrossRefPubMed
24.
Schildkraut JM, Goode EL, Clyde MA, Iversen ES, Moorman PG, Berchuck A, Marks JR, Lissowska J, Brinton L, Peplonska B, et al: Single nucleotide polymorphisms in the TP53 region and susceptibility to invasive epithelial ovarian cancer. Cancer Res. 2009, 69 (6): 2349-2357. 10.1158/0008-5472.CAN-08-2902.CrossRefPubMedPubMedCentral
25.
Sagne C, Marcel V, Amadou A, Hainaut P, Olivier M, Hall J: A meta-analysis of cancer risk associated with the TP53 intron 3 duplication polymorphism (rs17878362): geographic and tumor-specific effects. Cell Death Differ. 2013, 4 (2): e492-CrossRef
26.
Husgafvel-Pursiainen K, Kannio A: Cigarette smoking and p53 mutations in lung cancer and bladder cancer. Environ Health Perspect. 1996, 104 (Suppl 3): 553-556. 10.1289/ehp.96104s3553.CrossRefPubMedPubMedCentral
27.
Pfeifer GP, Denissenko MF, Olivier M, Tretyakova N, Hecht SS, Hainaut P: Tobacco smoke carcinogens, DNA damage and p53 mutations in smoking-associated cancers. Oncogene. 2002, 21 (48): 7435-7451. 10.1038/sj.onc.1205803.CrossRefPubMed
28.
Dagher Z, Garcon G, Billet S, Gosset P, Ledoux F, Courcot D, Aboukais A, Shirali P: Activation of different pathways of apoptosis by air pollution particulate matter (PM2.5) in human epithelial lung cells (L132) in culture. Toxicology. 2006, 225 (1): 12-24. 10.1016/j.tox.2006.04.038.CrossRefPubMed
29.
Soberanes S, Panduri V, Mutlu GM, Ghio A, Bundinger GR, Kamp DW: p53 mediates particulate matter-induced alveolar epithelial cell mitochondria-regulated apoptosis. Am J Respir Crit Care Med. 2006, 174 (11): 1229-1238. 10.1164/rccm.200602-203OC.CrossRefPubMedPubMedCentral
30.
Wakai K, Inoue M, Mizoue T, Tanaka K, Tsuji I, Nagata C, Tsugane S: Tobacco smoking and lung cancer risk: an evaluation based on a systematic review of epidemiological evidence among the Japanese population. Jpn J Clin Oncol. 2006, 36 (5): 309-324. 10.1093/jjco/hyl025.CrossRefPubMed
Metadata
Title
TP53 genetic polymorphisms, interactions with lifestyle factors and lung cancer risk: a case control study in a Chinese population
Authors
Yanli Li
Shen-Chih Chang
Rungui Niu
Li Liu
Christina R Crabtree-Ide
Baoxing Zhao
Jianping Shi
Xiaoyou Han
Jiawei Li
Jia Su
Lin Cai
Shunzhang Yu
Zuo-Feng Zhang
Lina Mu
Publication date
01-12-2013
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2013
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-13-607

Other articles of this Issue 1/2013

BMC Cancer 1/2013 Go to the issue

Research article

Advance lung cancer inflammation index (ALI) at diagnosis is a prognostic marker in patients with metastatic non-small cell lung cancer (NSCLC): a retrospective review

Research article

Association of plasma endotoxin, inflammatory cytokines and risk of colorectal adenomas

Research article

Differential outcome of concurrent radiotherapy plus epidermal growth factor receptor inhibitors versus radiotherapy plus cisplatin in patients with human papillomavirus-related head and neck cancer

Research article

Derepression of Cancer/Testis Antigens in cancer is associated with distinct patterns of DNA Hypomethylation

Research article

Patients’ perspectives on palliative chemotherapy of colorectal and non - colorectal cancer: a prospective study in a chemotherapy- experienced population

Research article

Forced expression of the DEK-NUP214 fusion protein promotes proliferation dependent on upregulation of mTOR
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits